On Feb. 24, OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) and Sarah Cannon announced that patient enrollment has been completed in the Spruce™ clinical trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating apatorsen in combination with carboplatin and pemetrexed in patients with previously untreated, advanced, non-squamous, non-small cell lung cancer (NSCLC). Spruce is sponsored and led by Sarah Cannon Research Institute (SCRI), the research arm of Sarah Cannon, Hospital Corporation of America’s (HCA) global cancer enterprise, and is being conducted at 16 sites across the United States . On Tuesday shares of OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) closed at $2.60.
Analysts at Barclays assumed coverage on shares of Chimerix (NASDAQ:CMRX) in a research report issued to clients and investors on Tuesday. The firm set an “overweight” rating on the stock. Chimerix, Inc. (NASDAQ:CMRX) in last trading activity increased 0.02% to close at $40.49. Company weekly performance is -2.22% while its quarterly performance stands at 14.90%. Chimerix, Inc. (NASDAQ:CMRX) is -6.73% away from its 52 week high.
Cognizant Technology Solutions Corporation (NASDAQ:CTSH) announced that Karen McLoughlin, Chief Financial Officer, presented at Morgan Stanley Technology, Media & Telecom Conference 2015, on Monday, March 2, 2015.On last trading day Cognizant Technology Solutions Corporation (NASDAQ:CTSH) decreased -0.22% to close at $62.78. Its volatility for the week is 1.24% while volatility for the month is 1.85%. CTSH’s sales growth for past 5 years was 25.60% and its EPS growth for past 5 years was 21.40%. Cognizant Technology Solutions Corporation (NASDAQ:CTSH) monthly performance is 15.98%.
Pilgrim’s Pride Corporation (NASDAQ:PPC) announced that it is offering $500.0 million aggregate principal amount of Senior Unsecured Notes due 2025 (the “Notes”) to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pilgrim’s Pride Corporation (NASDAQ:PPC) has 0.10% insider ownership while its institutional ownership stands at 34.50%. In last trading activity company’s stock closed at $28.61.
On Feb. 27, MaxLinear, Inc. (NYSE:MXL) and Entropic Communications, Inc. (NASDAQ:ENTR) announced that the U.S. Federal Trade Commission (FTC) has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to MaxLinear’s pending acquisition of Entropic. On last trading day Entropic Communications, Inc. (NASDAQ:ENTR) remains unchanged to close at $3.00. Its volatility for the week is 1.35% while volatility for the month is 2.56%. ENTR’s sales growth for past 5 years was 10.50% and its EPS growth for past 5 years was -41.80%. Entropic Communications, Inc. (NASDAQ:ENTR) monthly performance is 15.83%.